Daxotel 80 mg/vial (IV Infusion)

80 mg vial: ৳ 10,000.00

Medicine Details

Docetaxel is an antineoplastic agent that disrupts the microtubular network in cells, inhibiting mitosis and cellular functions

Indicated for Breast Cancer (BC) as a single agent for locally advanced or metastatic BC after chemotherapy failure
Indicated for Non-small Cell Lung Cancer (NSCLC) as a single agent for locally advanced or metastatic NSCLC after platinum therapy failure
Indicated for Castration-Resistant Prostate Cancer (CRPC) with prednisone in metastatic CRPC
Indicated for Gastric Adenocarcinoma (GC) with cisplatin and fluorouracil for untreated, advanced GC including the gastroesophageal junction
Indicated for Squamous Cell Carcinoma of the Head and Neck (SCCHN) with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN

Acts by disrupting the microtubular network in cells
Promotes the assembly of tubulin into stable microtubules
Inhibits disassembly of microtubules
Binds to free tubulin, decreasing the critical intracellular concentration of tubulin

Administer intravenously over 1 hr every 3 weeks
Dosage ranges for different indications
PVC equipment not recommended, use only a 21 gauge needle to withdraw docetaxel from the vial
Premedicate with oral corticosteroids
Adjust dose as needed

CYP3A4 substrate, metabolism may be modified by concomitant administration of certain compounds

Neutrophil counts of <1500 cells/mm3
History of severe hypersensitivity reactions to docetaxel or drugs formulated with polysorbate 80

Common adverse reactions include infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, myalgia
Incidence varies depending on the indication

Administered under supervision of a physician experienced in antineoplastic agents
Higher risk of severe adverse reactions in patients with hepatic impairment
Not to be given to patients with neutrophil counts of less than 1,500 cells/mm3
Fatal cases of enterocolitis reported, close monitoring required
Severe hypersensitivity reactions may occur, close monitoring required
Treatment related acute myeloid leukemia may occur

No known antidote for docetaxel overdose
Complications may include bone marrow suppression, peripheral neurotoxicity, mucositis
Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose

Store between 2°C and 25°C, protected from light, freezing does not adversely affect the product